TRAP-Induced Platelet Reactivity Is Inhibited by Omega-3 Fatty Acid-Derived Prostaglandin E3 (PGE3)
José-Miguel Osete1, Faustino García-Candel2,3, Francisco-José Fernández-Gómez4
1Department of Physiology, University of Murcia, 30120 Murcia, Spain.
Biomedicines
|January 8, 2025
Summary
Prostaglandin E3 (PGE3) from omega-3 fatty acids inhibits platelet activation by balancing opposing receptor signals. This reveals a mechanism for omega-3s' cardioprotective effects.
Area of Science:
- Cardiovascular Science
- Platelet Biology
- Pharmacology
Background:
- Prostaglandins modulate the cardiovascular system via Gs/Gi-coupled receptors.
- Omega-3 fatty acids are precursors to PGE3, a key mediator.
- Thrombin regulates platelet reactivity and coagulation.
Purpose of the Study:
- Investigate PGE3 effects on Thrombin Receptor Activating Peptide (TRAP-6)-induced platelet reactivity.
- Determine the receptors and mechanisms involved in PGE3 action.
- Elucidate the role of omega-3 fatty acids in cardioprotection.
Main Methods:
- Measured platelet aggregation, P-selectin expression, and VASP phosphorylation.
- Utilized selective EP3 and EP4 receptor antagonists (DG-041, ONO-AE3-208).
- Assessed changes in cyclic AMP (cAMP) levels via VASP phosphorylation.
Main Results:
- PGE3 inhibited TRAP-6-induced platelet aggregation and activation.
- Inhibition was potentiated by an EP3 antagonist and abolished by an EP4 antagonist.
- PGE3 effects correlated with altered cAMP levels, indicated by VASP phosphorylation.
Conclusions:
- PGE3 exerts dual effects on platelet reactivity through receptors with opposing effects on adenylate cyclase.
- This balance of activation and inhibition explains PGE3's impact on platelet function.
- Findings suggest a mechanism for omega-3 fatty acids' cardioprotective benefits.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
01:22Formation of the Platelet Plug
4.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
4.2K
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
342
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
342
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:11IP3/DAG Signaling Pathway
11.9K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
11.9K